Richard Kennedy

Richard Kennedy
Main position/role:
Global Vice President and Medical Director at Almac Diagnostic Services
Richard is the Global Vice President and Medical Director at Almac Diagnostic Services. He graduated in medicine from Queen’s University Belfast in 1995. As a post-graduate he trained as a medical oncologist and received a PhD in Molecular Biology in 2004. From 2004-2007 he worked as an Instructor in Oncology at Harvard Medical School, USA, where he identified novel biomarkers and drug targets for cancer treatment. This work was published in several high impact journals and the associated patent was in-licensed by a Boston-based start-up company in 2007. In August 2007 he joined Almac Diagnostic Services, part of the Almac Group, an international contract research and manufacturing organisation. In this role he has been involved in the design and international delivery of over 100 clinical trials using biomarkers on behalf of multiple large pharmaceutical companies. In 2011 he also established a research group at Queen’s University of Belfast focussed on various aspects of precision medicine. He currently sits on the MATRIX NI Government science advisory panel and Faculty of Pharmaceutical medicine Oncology expert group and has recently been involved in the response to COVID-19 as a committee member of the NI COVID-19 Testing Consortium. He completed his tenure as a member of the CR-UK new agents committee this year. 
Author: Admin